Newly reported from ACC 2024 – Sara Saberi, MD: FOREST-HCM Data Demonstrates Long-Term Effects of Aficamten
Newly reported from ACC 2024 – Sara Saberi, MD: FOREST-HCM Data Demonstrates Long-Term Effects of Aficamten Data from a 46-person cohort with 1 year of follow-up from the FOREST-HCM trial provides clinicians with further insight into the long-term effects of aficamten in patients with hypertrophic cardiomyopathy. Presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific […]
ACC.24 Clinical Trials Recap, with Deepak Bhatt, MD, MPH, MBA
ACC.24 Clinical Trials Recap, with Deepak Bhatt, MD, MPH, MBA Evidenced by the more than 17,000 attendees, the American College of Cardiology 2024 (ACC.24) Annual Scientific Session served as a showcase for the latest in clinically impactful advancements for the cardiology community. Although the sheer number of attendees serves as a testimony to the field’s seat at […]
Experts’ Perspectives: Advancements in Cardiomyopathy at ACC.24
Experts’ Perspectives: Advancements in Cardiomyopathy at ACC.24 In recent years, advancements in the treatment of cardiomyopathies have captivated the cardiology. However, experts and opinion leaders in cardiomyopathy are quick to remind others this progress was not overnight and comes as the result of tireless efforts by colleagues and their predecessors dating back decades. In the […]
Broadcasted from ACC 2024: Web App Could Improve Statin Therapy Without Need for Clinician Prescription
Broadcasted from ACC 2024: Web App Could Improve Statin Therapy Without Need for Clinician Prescription A study examines use of a web application to improve access to nonprescription statin therapy highlights the potential of digital interventions in improving population-level health. Results of the 6-month prospective study indicate use of the Technology Assisted Self-Selection (TASS) web application, which […]
ACC.24 Case Report: Leadless Pacemaker Extractions, with José López, MD
ACC.24 Case Report: Leadless Pacemaker Extractions, with José López, MD A study detailing a case series is offering clinicians additional perspective into an evolving area: leadless pacemaker extraction. Presented by at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions on the 8-year anniversary of the FDA’s first approval for a leadless pacemaker, the study details 2 cases […]
ACC 2024: Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds
ACC 2024: Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds New data indicates obicetrapib monotherapy could provide a synergistic benefit on lipid particles when used in combination with ezetimibe in people already on high-intensity statin therapy. The presentation, which was delivered at the American College of Cardiology 2024 (ACC.24) Annual Scientific Session, comes just 2 days […]
News Coverage from ACC 2024: Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM
News Coverage from ACC 2024: Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM Data from the phase 2 IMPROVE-HCM trial suggest ninerafaxstat, a novel cardiac mitotrope, was well-tolerated and improved symptom burden among patients with nonobstructive hypertrophic cardiomyopathy (HCM). The data, which were presented at the American College of Cardiology 2024 (ACC.24) Annual […]
Newscasting from ACC 2024: SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD
Newscasting from ACC 2024: SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD New data from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions offers the cardiology community the latest insights into the effects of plozasiran in patients with severe hypertriglyceridemia. Results of the phase 2b SHASTA-2 trial, which assessed use of the investigational APOC3-targeted small […]
Newly reported from ACC 2024: Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF
Newly reported from ACC 2024: Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF A modified on-treatment analysis of the TRANSFORM-HF trial presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions showed no meaningful changes in study outcomes between torsemide and furosemide treatment in heart failure hospitalizations after discharge. “Even with that, we still saw the […]
Directly from ACC 2024: SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH
Directly from ACC 2024: SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH An analysis of the DELIVER trial from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions is providing clinicians with new insight into the effects of SGLT2 inhibition across the range of left ventricular hypertrophy among patients with […]
